People · Operator
Named in public records as an officer, director or promoter · active 2015–2019 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. | — | Biotechnology | Series D+ | $282.2M | $940.9M | 2019 |
| Millendo Therapeutics, Inc. | — | Pharmaceuticals | Series C | $106.5M | $1.8B | 2017 |
| Lysosomal Therapeutics, Inc. | — | Biotechnology | Series B | $38.0M | $39.7M | 2015 |
Carole Neuchterlein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carole Neuchterlein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jack Nielsen | 1 | 13 |
| Bruce Booth | 1 | 12 |
| James Topper | 1 | 12 |
| Clay Thorp | 1 | 10 |
| Peter Hirth | 1 | 7 |
| Andrew J. Schwab | 1 | 7 |
| Peter Moldt | 1 | 6 |
| Carol Gallagher | 1 | 6 |
| Daniel Geffken | 1 | 6 |
| Robert Carpenter | 1 | 5 |
| Michael Yi | 1 | 4 |
| Steven E. Hall | 1 | 4 |
| John Fry | 1 | 4 |
| BERNARD DAVITIAN | 1 | 4 |
| William J. Harrington | 1 | 3 |
| Kathleen Glaub | 1 | 3 |
| Lawrence Blatt | 1 | 3 |
| Henri Termeer | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Bruce L Booth | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.